Advancing Care in Unresectable Hepatocellular Carcinoma

To participate in this activity, please:

Hepatocellular carcinoma (HCC) prevalence is currently increasing and is a major source of morbidity and mortality in the US and around the world. Management of HCC requires multidisciplinary collaboration across several specialties, with hepatologists and oncologists fulfilling key roles within the care team. Dr. Amit Singal provides learners with a comprehensive review of HCC, beginning with the epidemiology and burden of disease and taking learners through optimal systemic management. Dr. Singal will provide practical guidance related to the use of tyrosine kinase inhibitors, VEGF inhibitors, and immunotherapy in patients with HCC, including guideline recommendations, adverse event management, and the role of combination therapy.

Course Credit:

1.25 AMA PRA Category 1 CreditsTM


Opens: 2021-03-18
Closes: 2022-03-18

Target Audience:

This activity was developed for national audience of heptalogists, as well as medical and radiation oncologists, interventional radiologists, and hepatic surgeons.

This educational activity is supported by medical education grants from Bayer HealthCare Pharmaceuticals; Exelixis, Inc.; and Novocure Inc.

    Presenting Faculty

  • Amit G. Singal, MD, MS

    Chief of Hepatology
    Medical Director, Liver Tumor Program
    Professor, Department of Internal Medicine
    UT Southwestern Medical Center
    Dallas, Texas